IP Library Granted Patent US 9,417,243
Granted Patent B2
US 9,417,243 · App. 14/507,667 · Granted Aug 16, 2016

Systems and methods for anti-PAX8 antibodies

Inventors: Weimin Qi (Martinez, CA); David Tacha (Vacaville, CA)
Assignee: Biocare Medical, LLC
G01N33/5748C07K16/18C07K16/32G01N33/574C07K2317/24C07K2317/34C07K2317/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,417,243
App. No.
14/507,667
Granted
Aug 16, 2016
Kind
B2
Abstract

The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.

Claims (42)

1. An antibody or fragment thereof that specifically binds to the amino acid sequence consisting of SEQ ID NO: 3.

2. An antibody or fragment thereof according to claim 1 wherein said antibody or fragment thereof comprises a polypeptide of the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2.

3. An antibody or fragment thereof according to claim 1 wherein said antibody or said fragment thereof comprises a light chain variable region comprising the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 2 and a heavy chain variable region comprising the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 1.

4. An antibody or fragment thereof according to claim 1 wherein said antibody or said fragment thereof binds specifically to at least PAX8.

5. An antibody or fragment thereof according to claim 4 wherein said antibody or said fragment thereof which binds specifically to at least PAX8 comprises an antibody or fragment thereof which binds specifically to at least PAX8 and does not bind to B-cells.

6. An antibody or fragment thereof according to claim 4 wherein said antibody or said fragment thereof which binds specifically to at least PAX8 comprises an antibody or fragment thereof which binds specifically to at least PAX8 and does not specifically bind to cells selected from a group consisting of neuroendocrine cells, pancreatic cells, and any combination thereof.

7. A composition according to claim 1 comprising said antibody or fragment thereof that specifically binds to at least one polypeptide with an amino acid sequence comprising residues of SEQ ID NO: 3 and at least one other antibody or fragment thereof.

8. A composition according to claim 7 wherein said at least two antibodies or fragments thereof are obtained from at least two different species.

9. A composition according to claim 8 wherein said at least two different species is selected from a group consisting of mouse, rabbit, goat, horse, chicken, human, and any combination thereof.

10. A composition according to claim 7 wherein said at least two antibodies or fragments thereof are used in a double-stain procedure.

11. A composition according to claim 7 wherein said at least two antibodies or fragments thereof are used in a staining procedure capable of providing different visualization results.

12. A composition according to claim 11 wherein said visualization results comprise color results.

13. A composition according to claim 7 wherein said at least one other antibody or fragment thereof binds specifically to an antigen selected from a group consisting of GATA-3, p63, PSA, ER, Mammaglobin, GCDFP-15, NKX3.1, Napsin A, TTF-1, CK20, CDX2, ERG, and any combination thereof.

14. A composition according to claim 7 wherein at least two antibodies or fragments thereof each bind specifically to proteins selected from a group consisting of:

PAX8 and GATA-3;

PAX8 and p63;

PAX8 and PSA;

PAX8 and PSA and GATA-3;

PAX8 and ER and Mammoglobin and GCDFP-15;

PAX8 and ER;

PAX8 and Mammoglobin;

PAX8 and GCDFP-15;

PAX8 and NKX3.1;

PAX8 and Napsin A and TTF-1;

PAX8 and Napsin A;

PAX8 and TTF-1;

PAX8 and CD20 and CDX2;

PAX8 and CD20;

PAX8 and CDX2;

PAX8 and ERG and GATA-3; and

PAX8 and ERG.

15. An antibody according to claim 1 wherein said antibody comprises a monoclonal antibody.

16. An antibody according to claim 15 wherein said monoclonal antibody is selected from a group consisting of a mouse monoclonal antibody, a rabbit monoclonal antibody, a goat monoclonal antibody, a horse monoclonal antibody, a chicken monoclonal antibody, a humanized monoclonal antibody, a chimeric antibody, and any combination thereof.

17. An antibody according to claim 1 wherein said antibody comprises an isolated antibody.

18. An antibody according to claim 1 wherein said fragment thereof comprises an antigen binding fragment thereof.

19. An antibody according to claim 1 and further comprising a label attached to said antibody or fragment thereof.

20. An antibody according to claim 19 wherein said label is selected from a group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, and any combination thereof.

21. A method for detecting PAX8 in a biological sample comprising the steps of:

contacting a biological sample with said antibody or fragment thereof according to claim 1 ; and

detecting binding of said antibody with an antigen in said biological sample using said antibody detection element.

22. A method according to claim 21 wherein said biological sample is selected from a group consisting of a normal tissue, neoplastic tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, bladder tissue, prostate tissue, lung tissue and breast tissue.

23. A method according to claim 21 wherein said detecting comprises a method selected from a group consisting of immunohistochemistry (IHC), IHC of FFPE, ICH of frozen-tissue sections, and ELISA.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2026
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 075082/0723 →
SECURITY INTEREST Recorded Dec 9, 2021
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 058344/0799 →
RELEASE OF SECURITY INTEREST Recorded Dec 9, 2021
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 058351/0058 →
SECURITY INTEREST Recorded Aug 25, 2017
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 043401/0661 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 034054 FRAME: 0264. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 15, 2014
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, LLC
Reel/Frame 034631/0056 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2014
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, INC.
Reel/Frame 034054/0264 →
Continuity (4)
Continuation 14004400
Provisional Application 61484579 · May 10, 2011
Provisional Application 61588035 · Jan 18, 2012
Related Publication 20150056635A1 · Feb 26, 2015